For the 5th time, Team Red Glead receives the DI Gasell award – an annual recognition of the fastest growing companies in Sweden
Five times during the last six years, Red Glead Discovery AB has been recognized as a Gasell company by Scandinavia’s largest business paper, Dagens Industri. The award is given annually to fast-growing and profitable Swedish companies with sound finances (less than 1% of companies qualify).
Red Glead Discovery was founded as a drug discovery company by 7 scientists in 2011, after the closure of the AstraZeneca site in Lund. Since the start Red Glead has continuously grown its revenues and the annual growth rate is currently at 33% (as an average over the last three financial years). During the last year, the organisation of approximately 55 employees has been significantly strengthened to support the continuous expansion. This includes the recruitment of a chief financial officer and a human resources manager.
Working together in cross-functional research and development teams, our customers’ drug discovery projects are delivered with speed and high quality. Red Glead Discovery has helped clients to discover or progress several small molecule candidates into preclinical development. Four of these candidates are now in clinical trials, as potential treatments of for example CNS and cancer indications. Altogether, over 250 companies and organisations including international biotech and pharma have been served since 2011.
Working towards better health for people and planet, Red Glead Discovery proves its commitment to building not only a sustainable economy, but also a sustainable future. This is done by having set emissions reduction targets through the Science Based Targets initiative, with levels required to meet the goals of the Paris Agreement.
Red Glead Discovery also engage in internal or co-owned research and development activities related to new technologies and drug targets, often performed in collaboration with academia or industry. Recent partnering with a leading artificial intelligence company to develop and deliver a novel tool for drug discovery was initiated earlier this year. This project intends to further support clients with their drug discovery efforts through increased speed, reduced cost and climate footprint.
Johan Evenäs, CEO at Red Glead says: “Becoming a 2022 DI Gasell fits our strategy to become a leading, innovative, and sustainable European drug discovery company. I am very proud of our dedicated co-workers and thankful for our many great collaborations with clients, suppliers and partners.”
About Di Gasell
Since over twenty years, Dagens Industri has listed Sweden’s most successful and fast-growing companies. The ranking is based on the company’s four most recent annual reports. Some of the criteria include at least doubled turnover, increased turnover every year for the past three years, organic growth (not through mergers/acquisitions). A Gasell company serves as a role model for other companies and drives business growth in Sweden.
About Red Glead Discovery AB
Red Glead Discovery is a leading Scandinavian provider for integrated drug discovery contract research and supports customers in the Life Science industry to develop their ideas for new drugs. Red Glead Discovery is located at Medicon Village and Ideon in Lund, Sweden. www.redglead.com
For more information, please contact Johan Evenäs, 046–4601291, email@example.comBack